OCs and VTE: a practical answer to an old question

In a recent commentary in this journal, Jürgen Dinger1 argued that “the risk of VTE [venous thromboembolism] attributable to OCs [combined oral contraceptives] is a class effect, primarily dependent on the dose of estrogen” and that the type of progestogen used in the OC probably does not influence this risk. In an editorial in the British Medical Journal that accompanied the publication of the two largest studies to date on this topic, Nick Dunn2 concluded: “All of the more recent progestogens, possibly except norgestimate, now seem to be at a disadvantage with regard to VTE”.

As VTE is a very rare event, it is unreasonable to expect the answer to the progestogens and VTE question from a randomized controlled trial. We may thus never be able to exclude residual confounding as a possible explanation for the higher VTE rates found with newer progestogens.

Luckily in clinical practice this does not matter much. For OCs, as for any treatment, health professionals should first consider the safest and most effective treatment, and in the absence of knowledge differences between treatments we should then consider costs.

Most patients requesting a OC request it solely for contraception. Most of these patients will be satisfied with a COC containing a second-generation progestogen, usually levonorgestrel (LNG). Dr Dinger does not question that COCs containing LNG are at least as safe and effective as those containing one of the newer progestogens.

The basket of care offered by sexual health services is constantly changing. More than was the case in the past, we promote subdermal and intrauterine methods and offer sexually transmitted infection (STI) and HIV screening and manage genital tract infection. To afford to do this we have to keep costs as low as possible. Where budgets are finite and probably shrinking, the cost of prescribing COCs containing a newer progestogen instead of LNG can be measured in fewer implants or intrauterine methods inserted and fewer chlamydia or HIV tests undertaken.

This is as good a reason as any to adhere to Faculty Guidance on ‘First Prescription of Combined Oral Contraception’, which states: ‘A monophasic COC containing 30 µg ethinyl estradiol with norethisterone or levonorgestrel is a suitable first pill (Grade C)’.

Rudiger Pittrof, MS, MRCOG
Consultant, Enfield Community Services, Reproductive and Sexual Health (RASH), London, UK.
E-mail: rudiger.pittrof@enfield.nhs.uk

Ulrike Sauar, MD
Specialist Registrar, Enfield Community Services, Reproductive and Sexual Health (RASH), London, UK.

References

Drospirenone and VTE

Following publication in the October 2009 issue of this commentary article regarding the risk of venous thromboembolism (VTE) with combined oral contraceptives (OCs) and subsequent criticisms,1,2 we would like to share some information regarding prescribing in Zagreb, Croatia of a recently introduced COC, containing 3 mg drospirenone and 30 µg ethinyl estradiol (DRSP/EE) (Yazone). We collected data in the city of Zagreb during the period 2004–2008, employing various data sources as follows: data on inpatients from Zagreb; data on the causes of hospitalisation; data on side effects from the Agency for Drugs and Medicinal Products; and data on drug use from Zagreb pharmacies. The total female population under surveillance was approximately 500 000.

In Zagreb, use of OCs in general increased by 31% between 2004 and 2008. This rising trend was especially pronounced after 2005, when the combination DRSP/EE was introduced. In 2005, DRSP/EE accounted for 15.4% of the overall utilisation of OCs, which increased to 57.7% in 2008, yielding a 4.4-fold increase. Other OCs classified as fixed combinations of progestogens and estrogens showed a decrease in

preferential prescribing of certain progestogens or groups thereof. This would also not be possible on the basis of VTE risk, because it is quite conceivable that progestogens do not differ at all or do differ only slightly in their VTE risk but could well differ with respect to other risks – for example, of arterial thromboembolic events such as acute myocardial infarction and stroke.

In addition to the above, there is a difference with regard to a number of pharmacological characteristics, such as anti- androgenic and antimineralocorticoid properties. While manufacturers’ sales organizations may well overemphasize differences in the pharmacological profiles of progestogens, this does not mean that these differences are negligible in clinical practice.

At a time when it is becoming increasingly difficult to finance health care, cost-conscious use of pharmaceutical products should not be a taboo topic – especially if these products are not paid for by the patients or users themselves. This applies, for example, to OCs in the UK – in contrast to the vast majority of other countries. Here I would agree with Drs Pittrof and Sauer. However, I am also explicitly in favour of discussing and critically examining safety concerns that are published about certain groups of OCs yet that are of debatable scientific merit owing to the large differences of the price tags on these products. Any other position on this matter would be scientifically questionable as well as irresponsible. The debate surrounding second- and third-generation OCs has made us all aware of how easily quick claims about safety can become a full-fledged ‘pill scare’ that does not remain focused on a certain group of products but instead leads to an overall drop in OC use. That can, in turn, lead to increased abortion rates, and does a disservice to women who do not wish to become pregnant.

Jürgen Dinger, MD, PhD
Director, Berlin Centre for Epidemiology and Health Research, Berlin, Germany.
E-mail: dinger@czg-berlin.de

References

Filshie clip migration and retention

We wish to advise journal readers about an unusual case of Filshie clip migration and retention inside the ureteral cavity that to our knowledge has never been reported before.

A 68-year-old woman, with three previous vaginal births, presented with postmenopausal bleeding for 2 weeks. She underwent a laparoscopic Filshie clip sterilisation 25 years ago and had been menopausal for 16 years. An ultrasound scan suggested an endometrial polyp that was confirmed on hysteroscopy. A closed Filshie clip was seen within the ureteral cavity and attached to the polyp by filmy adhesions. The clip was removed along its longitudinal axis with forceps after dilation of the ureteral ostium. The ureteral ostium was not evident except for a small dimple at its expected site. Histology confirmed a benign endometrial polyp.

The clip was lying freely inside the ureteral cavity without being expelled. The likely sequence of events could have been a low-grade foreign body inflammatory reaction that resulted in incorporation and subsequent burrowing of the clip through the ureteral wall into its cavity. Burrowing and migration through the Fallopian tube is also a possibility and could explain the closure of the right ostium by post-inflammatory adhesions.

Laparoscopic sterilisation with Filshie clip remains a popular method of permanent contraception since its introduction by Markus Filshie in 1981. It is a safe and effective method, with a failure rate of 1 in 200.1 The 12.7 mm long and 4 mm wide titanium clip is lined with silicone rubber and is closed round the Fallopian tube by means of an applicator leading to avascular tubal necrosis. The tube eventually divides and the stumps heal leaving two occluded ends.2 The clip usually remains attached to the site of tubal separation and becomes detached if a delay in uterine cavity. This delay may be the cause of enteralisation, the clip may become detached and migrate through tissue planes. This is estimated to occur in 0.6 per 1000 cases.3 Detached clips are most commonly found within the peritoneal cavity, typically in the Pouch of Douglas or the paracolic gutters. Migration to the urinary bladder, vagina, rectum and into the peritoneum leading to an ischiorectal abscess has...
OCs and VTE: a practical answer to an old question

Rudiger Pittrof and Ulrike Sauer

*J Fam Plann Reprod Health Care* 2010 36: 44
doi: 10.1783/147118910790291046

Updated information and services can be found at:
http://jfprhc.bmj.com/content/36/1/44.1.citation

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/